华润医药(03320.HK)中期净利润25.77亿港元 同比减少15.1%
格隆汇8月27日丨华润医药(03320.HK)公告,截至2020年6月30日止6个月,公司总收益达港币893.87亿元,同比减少12.3%(按照人民币口径,报告期间内集团总收益较上年同期减少8.1%)。上半年制药、医药分销、药品零售三个主要业务分部的收益占比分别为14.0%、82.5%以及3.3%。
报告期间内集团实现毛利港币148.67亿元,同比减少14.7%(以人民币口径同比减少10.7%);整体毛利率为16.6%,与2019年上半年的毛利率17.1%相比略下降0.5个百分点,主要因为报告期间内毛利率相对高的制药业务收益降幅超过分销业务,以及制药业务的平均毛利率有所下降的综合原因所致。
期间实现公司拥有人应占溢利港币25.77亿元,同比减少15.1%。如剔除深圳市三九医院有限公司处置等一次性项目影响,报告期间内集团拥有人应占溢利同比实现增长7.9%。
报告期间内,集团制药业务实现分部收益港币139亿元,同比下降20.0%,按照人民币口径同比下降16.2%,主要因为疫情影响导致集团处方药业务收入下滑,以及东阿阿胶继续进行库存调降、上半年业绩同比下滑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.